Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

E
W-043
Early sBCMA Kinetics as a Potential Indicator of Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Patients Receiving CAR T-Cell Therapy

Favorite
W-015
Eculizumab as a Key Comparator for the Evaluation of Complement Targeted Novel Therapeutic Strategies with a QSP Model

Favorite
W-078
Effect of Convenience Sampling on Overall Drug Exposure during Pregnancy

Favorite
W-054
Effects of sparse sampling in the characterization of leuprolide pharmacokinetics and pharmacodynamics in patients with prostate cancer

Favorite
T-075
Enhancing Parameter Estimation Process for Pharmacokinetic-Pharmacodynamic Models with Meta-heuristic Optimization Approaches

Favorite
M-142
Evaluating concomitant medication use in cystic fibrosis patients using real-world data (RWD) to inform drug-drug interaction risk assessment and clinical trial design of GDC-6988

Favorite
M-023
Evaluating the Importance of Glucagon in the Insulin-Glucose Regulatory System: A Mechanistic Modeling Approach

Favorite
M-103
Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM

Favorite
W-037
Evaluation of Large Language Models for an AI Chat Assistant Focused on Pumas and Pharmacometrics

Favorite
M-112
Evaluation of Praziquantel Exposures in Children Dosed Using Different Body Weight Estimation Methods

Favorite
M-104
Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model

Favorite
W-118
Evaluation of the population pharmacokinetics of pexmetinib in a simultaneous model of two formulations

Favorite
M-125
Explore the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – a Modeling Approach

Favorite
W-069
Exploring Appropriate Prior Distributions for Covariance Matrix Estimation in Bayesian Population Pharmacokinetic Analysis

Favorite
M-041
Exploring Best Practices of the Population Pharmacokinetic Modeling for Antibody-Drug Conjugates – a Simulation Study

Favorite
W-084
Exploring the feasibility of using AI to identify patient characteristics predictive of histological endpoints in metabolic dysfunction associated steatohepatitis (MASH)

Favorite
M-074
Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer

Favorite
T-058
Exposure-response (E-R) relationship between PD-L1 recombinant monoclonal antibody IMC-001 in relapsed or refractory extranodal NK/T cell lymphoma nasal type patients

Favorite
W-074
Exposure-response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Favorite
W-049
Exposure-Response Analysis for Hepatotoxicity of Rivoceranib Monotherapy and in Combination with Camrelizumab in Patients with Various Cancers, Including Advanced Hepatocellular Carcinoma

Favorite
M-050
Exposure-Response Analysis of Cenobamate

Favorite
T-037
Exposure-Response Efficacy and Safety Analysis of Repotrectinib to Support the Dose Recommendation for Patients with ROS1-positive NSCLC

Favorite
T-072
Exposure–Response Relationship of Dostarlimab With Chemotherapy in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis Two of Part 1 of ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

Favorite
W-040
Extracting Lab Value Reference Ranges from Neonatal Real-World Data in OMOP Format

Favorite
W-065
Extrapolation of Efficacy and Simplification and Optimization of Pediatric Clinical Trial Design for Azilsartan Medoxomil (Edarbi) through Modeling and Simulation

Favorite